Literature DB >> 8451780

Lack of pharmacokinetic interaction between chloroquine and imipramine.

C O Onyeji1, T A Toriola, F A Ogunbona.   

Abstract

The pharmacokinetic interaction between chloroquine (CQ) and imipramine was investigated in six healthy volunteers who received 300 mg of CQ, 50 mg of imipramine, and combined doses of both drugs in a randomized, crossover design. Blood and urine samples were collected at predetermined time intervals and were analyzed for the drugs and their metabolites by high-performance liquid chromatography methods. The results revealed that the plasma concentrations of CQ and its pharmacokinetic parameters were not significantly altered when CQ was coadministered with imipramine (p > 0.1). The plasma concentration-time profiles and the disposition characteristics of imipramine also were not altered after coadministration with CQ. The results suggest that there appears to be no pharmacokinetic interaction between CQ and imipramine given as single oral doses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8451780     DOI: 10.1097/00007691-199302000-00008

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

Review 1.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.

Authors:  Haleh Rezaee; Fariba Pourkarim; Samira Pourtaghi-Anvarian; Taher Entezari-Maleki; Touraj Asvadi-Kermani; Masoud Nouri-Vaskeh
Journal:  Pharmacol Res Perspect       Date:  2021-02

Review 4.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

Review 5.  FIRST REPORTS OF CLINICAL PHARMACOKINETICS IN NIGERIA.

Authors:  O S Michael
Journal:  Ann Ib Postgrad Med       Date:  2015-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.